Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial
Journal of Radiation Research · 2026
DOI: 10.1093/jrr/rrag051 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Radiation Research, 2026. Verfasst von Takashi Iizumi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Proton Therapy, Radiation Dose Hypofractionation, Radiotherapy, Image-Guided. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: JSPS.
Abstract (Originalsprache)
The purpose of the present study is to confirm the efficacy and feasibility of moderately hypofractionated proton beam therapy (PBT) at a total dose of 63 Gy relative biological effectiveness (RBE) in 21 fractions for prostate cancer. This phase II clinical trial (PPS-002: UMIN 000017679) enrolled 125 men with histologically confirmed prostate cancer (cT1c-3aN0M0). The primary endpoint was grade ≥2 late gastrointestinal (GI) toxicities. Secondary endpoints included biochemical recurrence rates, clinical recurrence rates, overall survival (OS) and acute toxicities and late genitourinary (GU) toxicities. With a median follow-up period of 71.0 months (IQR: 60–84), the 5-year cumulative incidences of late grade 2 or higher GI and GU adverse events (AEs) were 3.3% and 8.1%, respectively. Biochemical recurrences were observed in three patients; no clinical recurrences occurred. The 5-year biochemical recurrence-free, clinical recurrence-free and OS rates were 97.6% (95% CI: 94.9–100.0), 100% and 97.5% (95% CI: 94.8–100.0), respectively. The long-term follow-up results of moderately hypofractionated PBT of 63 Gy (RBE) in 21 fractions confirmed low incidences of late AEs, successfully meeting the primary endpoint. Furthermore, the low incidence of tumor recurrence supports the overall safety and feasibility of this fractionation schedule.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan.
- QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba 263-8555, Japan.
- Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, 6528 Koibuchi, Kasama, Ibaraki 309-1793, Japan.
- Department of Radiation Oncology, Tsuchiura Kyodo General Hospital, 4-1-1, Otsuno, Tsuchiura, Ibaraki 300-0028, Japan.
- Department of Radiation Oncology, Hitachi General Hospital, Hitachi Ltd., 2-1-1 Jonancho, Hitachi, Ibaraki 317-0077, Japan.
- Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba 263-8555, Japan.
ORCID-Profile: Takashi Iizumi, Hitoshi Ishikawa, Masashi Mizumoto, Hideyuki Sakurai
Förderung
- JSPS
Zitieren
APA
Iizumi, T., Ishikawa, H., Sekino, Y., Murakami, M., Tanaka, K., Takizawa, D., Makishima, H., Mori, Y., Kamizawa, S., Mizumoto, M., Okumura, T., Suzuki, H., Nishiyama, H., & Sakurai, H. (2026). Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial. Journal of Radiation Research. https://doi.org/10.1093/jrr/rrag051
Vancouver
Iizumi T, Ishikawa H, Sekino Y, Murakami M, Tanaka K, Takizawa D, et al. Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial. Journal of Radiation Research. 2026. doi:10.1093/jrr/rrag051
BibTeX
@article{Iizumi2026,
author = {Iizumi, Takashi and Ishikawa, Hitoshi and Sekino, Yuta and Murakami, Motohiro and Tanaka, Keiichi and Takizawa, Daichi and Makishima, Hirokazu and Mori, Yutaro and Kamizawa, Satoshi and Mizumoto, Masashi and Okumura, Toshiyuki and Suzuki, Hiroyoshi and Nishiyama, Hiroyuki and Sakurai, Hideyuki},
title = {Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial},
journal = {Journal of Radiation Research},
year = {2026},
doi = {10.1093/jrr/rrag051}
}
EUVIMED